0000950170-23-067738.txt : 20231204
0000950170-23-067738.hdr.sgml : 20231204
20231204160510
ACCESSION NUMBER: 0000950170-23-067738
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231130
FILED AS OF DATE: 20231204
DATE AS OF CHANGE: 20231204
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hecht Peter M
CENTRAL INDEX KEY: 0001478485
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38787
FILM NUMBER: 231462992
MAIL ADDRESS:
STREET 1: C/O CYCLERION THERAPEUTICS, INC.
STREET 2: 301 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cyclerion Therapeutics, Inc.
CENTRAL INDEX KEY: 0001755237
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 831895370
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 301 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-621-7722
MAIL ADDRESS:
STREET 1: 301 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
ownership.xml
4
X0508
4
2023-11-30
0001755237
Cyclerion Therapeutics, Inc.
CYCN
0001478485
Hecht Peter M
C/O CYCLERION THERAPEUTICS, INC.
245 FIRST STREET, 18TH FLOOR
CAMBRIDGE
MA
02142
true
false
true
false
false
Common Stock
2023-11-30
4
A
false
20000
0
A
347385
D
Common Stock
2023-12-01
4
A
false
15000
0
A
362385
D
Common Stock
24
I
The 2000 Trust for Alexis Mae Hecht
Common Stock
24
I
The 2000 Trust for Malcolm Peter Hecht
Common Stock
24
I
The 2000 Trust for Zoe Niovi Hecht
The Reporting Person was granted 20,000 shares of restricted stock pursuant to the Cyclerion Therapeutics, Inc. 2019 Equity Incentive Plan. 2,500 of the shares vest immediately and the remaining 17,500 shares are subject to vesting ratably over a 42-month period, provided that the Reporting Person remains as a director of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions.
The Reporting Person was granted 15,000 shares of restricted stock pursuant to the Cyclerion Therapeutics, Inc. 2019 Equity Incentive Plan. These 15,000 shares are subject to vesting over a 48- month period, provided that the Reporting Person remains a consultant to the Cyclerion Therapeutics or a member of the board of directors of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions.
These shares are held in the referenced trust for the benefit of the reporting person's child. The reporting person's spouse is the trustee of this trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or any other purpose.
/s/ Peter M Hecht
2023-12-04